PRESCRIBED BY CLINICIANS, APPLIED BY PATIENTS.

VERIS™, powered by collagen and Mānuka honey, is the first advanced wound care product to deliver on performance, ease, and affordability for the millions recovering from Mohs surgery, biopsies, and chronic ulcers.

Recovery starts with VERIS™

  • 2x faster wound closure (1-3*)

  • Lower Pain Reported (4*)

  • 99.99% bacteria reduction in 24 hrs (5*)

  • Inflammation reduction (6,7*)

  • Growth factor release (6,7*)

Effortless for Clinicians

  • Similar to a pharmaceutical product, VERIS™ is easily prescribed at the patient's visit.

  • Ordering takes seconds and SweetBio® supports EMR automation.

  • No inventory to carry, VERIS™ + supplies are shipped directly to the patient.

Empowering for Patients

  • Just like a mail-order prescription, VERIS™ arrives at the patient’s home with 30 days of wound supplies.

  • Provided in a convenient non-sticky sheet, VERIS™ is as simple as adding a layer under a bandage. Simply peel open, hydrate, place and cover.

  • For easy maintenance, VERIS™ dissolves daily as the wound progresses with no painful removal process.

Cost-effective

  • Similar to a pharmaceutical product, VERIS™ is prescribed at the patient’s visit at no cost or billing effort from the clinic. 

  • • VERIS™ is covered by Medicare and many commercial plans

    • VERIS™ is billed by insurances under HCPCS A6021 as a low-cost wound supply.

  • Unlike skin substitute wound care products, VERIS™ is offered at a fraction of the cost.

PATENTED MX® TECHNOLOGY

Unique Chemical Fingerprint, Broken Down to be Rebuilt.

  • SweetBio®’s MX® technology embodies a paradigm shift in biomaterials by liberating three natural ingredients from their limitations.

    We meticulously deconstructed natural elements to reimagine and rebuild a new biomaterial with a unique chemical fingerprint that transcends the mere sum of its parts.

    The deliberate selection of ingredients by biomedical engineers has led to the creation of revolutionary wound healing products tailored to address the specific demands of the healing process.

  • A natural extracellular matrix protein, an essential part of organic tissue. (8)

  • 100% UMF-certified New Zealand Mānuka honey, known for antibacterial properties and aiding in wound healing. (9)

  • A naturally occurring mineral known to add structural reinforcement to biomaterials. (10)

VERIS™ is Easy to Use

Clean the wound

Hydrate VERIS™ with saline

Apply VERIS™ and gently press to ensure it contacts the wound

Cover with bandage

“

VERIS™ is not just hastening the closure of wounds; it empowers patients to take control of their recovery at home. Seamless for me and simple for my patients.

— GWEN BEARD, MD MOHS SURGEON / MEMPHIS DERMATOLOGY

VERIS™ in Action

  • 2 lower leg biopsies performed by a board-certified Mohs surgeon.

  • 65-year-old female, Medicare-insured

  • Patient returned 2 weeks post-biopsies with no wound closure.

  • VERIS™ was prescribed by clinician. SweetBio® logistics partner fulfilled order and billed patient insurance at no charge to patient.

  • Patient changed their own dressings at home.

  • Wounds closed in 3-6 weeks, when expected time to closure was 12 weeks.

Before + After

*Pictures taken and shared with patient consent.

Backed by Evidence

  • Clinical Publication: 37 Patient Mohs Dermatologic Surgery RCT

    Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.

    Download

  • Clinical Publication: 12 Patient Lower Extremity Chronic Wound Case Series

    Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.

    Download

  • Clinical Publication: 8 Patient Mohs Dermatologic Surgery Case Series

    Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.

    Download

  • Clinical Publication: 43 Patient Chronic Wound Healing in an Urban Hospital Wound Clinic

    Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).

    Download

  • In Vitro Publication: Bacteria Reduction

    Published in Biomedical & Translational Science, this data demonstrates SweetBio®’s technology ability to significantly reduce both Staphylococcus Aureus and Pseudomonas Aeruginosa by 99.99% compared to a non-treated surface after 24 hours, in vitro.

    Download

  • In Vitro Publication: Controlling Inflammation and Growth Factors

    Published in the International Journal of Biomaterials, this data demonstrates SweetBio®’s technology ability to significantly decrease (to negligible levels) the expression of MMP-9 from macrophages and trigger the release of pro-regenerative growth factors from fibroblasts such as FGFb and VEGF, in vitro.

    Download

  • In Vitro Publication: Direct Comparison of Collagen Dressing vs. Manuka Honey Dressing vs. SweetBio®’s Technology

    Published in the International Journal of Molecular Sciences, this data highlights the superior comprehensive approach that SweetBio®’s technology has over collagen dressings and Manuka honey dressings, specifically comparing MMP-9/TIMP-1 ratios and pro-regenerative growth factor secretion, in vitro.

    Download

“

The easy-to-use packaging of VERIS™ has made self-application convenient, even while traveling, allowing me to maintain my wound care routine without hassle.

— VERIS™ PATIENT

Frequently Asked Questions

VERIS™ Overview

  • Whether surgically created or stalled, VERIS™ can be used on most wounds. VERIS™ is FDA-cleared for the management of a variety of wounds, including surgical sites (Mohs, biopsies, etc.) and ulcers (diabetic, venous stasis, pressure).

    Indications:

    Full and Partial-Thickness Wounds

    Pressure Ulcers (Stages I -IV)

    Venous Stasis Ulcers

    Diabetic Ulcers

    Surface Wounds

    Traumatic Wounds

    Surgical Wounds

    Abrasions

    Donor Sites

  • Powered by a patented combination of 3 natural ingredients, VERIS™ is a one-of-a-kind solution backed by science. Ingredients:

    • Collagen Derivative: A natural extracellular matrix protein, an essential part of organic tissue. (8)

    • 100% UMF™-Certified New Zealand Mānuka Honey: Known for antibacterial properties and aiding in wound healing. (9)

    • Hydroxyapatite: A naturally occurring mineral known to add structural reinforcement to biomaterials and promote wound healing via angiogenesis and re-epithelialization. (10)

  • VERIS™ was created by SweetBio, Inc. Learn more about SweetBio's mission and values here.

  • VERIS™ is made with SweetBio®’s technology, MX™, which addresses the wound's microenvironment by balancing key variables known to heavily impact both early stages (i.e., homeostasis and inflammatory phases) and late stages (i.e., proliferation and remodeling phases) of the wound healing process. (5-7*)

  • VERIS™ is covered by Medicare as a wound care supply (A6021, Collagen). Depending on the policy, VERIS™ may be covered by commercial plans.

  • There is no FDA-cleared claim for VERIS™ or any other Mānuka honey product on the market as an antibacterial product. However, Mānuka honey is well-researched for its antibacterial properties, and SweetBio®’s MX™ technology has demonstrated a remarkable 99.99% reduction in gram-positive and gram-negative bacteria in vitro, which is published in peer-reviewed journals. (5*)

  • Yes, the Mānuka honey used in VERIS™ is 100% UMF certified and medical grade, which is filtered and sterilized.

Using VERIS™

  • SweetBio® will provide an easy-to-follow script for you to support your patient’s expectations.

    Email info@sweetbio.com for patient educational materials.

  • VERIS™ is a sponge-like, non-sticky sheet with an off-white to golden color. As VERIS™ is made with natural ingredients, size, shape, texture and color may vary between products.

  • Several drops of saline are sufficient to prepare VERIS™. VERIS™ should be wet, not soaking or dripping, to avoid saturating the covering bandage. Note that VERIS™ may expand slightly as it hydrates with saline.

  • No, VERIS™ works well even when set in the wound bed and does not overlap the edges of the wound. Most importantly, VERIS™ must contact the wound bed. Press gently upon application to maximize wound bed contact.

  • No, VERIS™ can be applied with either side contacting the wound.

  • Contraindications

    • Patients with sensitivity to collagen and its derivatives

    • Patients with sensitivity to porcine-derived products

    • Patients with sensitivity to honey

    • Third degree burns

    • Infections or contamination in the wound site

    • Control of bleeding

    • Children and infant patients under 10kg / 22lbs

    Usage Information

    • Users should follow the most recent procedures and best practices for wound management to complete wound preparation, application of VERIS™ and application of secondary dressings.

    • Remove VERIS™ and discontinue use if signs of sensitivity appear.

    • Do not use VERIS™ after the expiration date stated on the product label.

    Contact a health care professional if:

    • Signs of infection occur (e.g. increased pain)

    • There is a change in wound color and/or odor

    • The wound does not begin to show signs of healing, or

    • Any other unexpected symptom

We’d love to hear from you!

The safety and well-being of our patients and those that care for them is what matters most. You can count on us through every step.

CITATIONS
1. Rodriguez et al. Novel bioengineered collagen + Manuka honey + hydroxyapatite sheet for the treatment of lower extremity chronic wounds in an urban hospital wound care setting. 2023.
2. Rodriguez et al. Preliminary clinical evaluation of a novel bioengineered wound product: A focus on the management of lower extremity ulcers. 2020.
3. McMurray et al. Use of a Novel Biomaterial to Enhance Secondary Intention Healing. 2021.
4. Arnaud et al. Novel Biomaterial Containing Gelatin, Manuka Honey, and Hydroxyapatite Enhanced Secondary Intention Healing Versus Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities-A Randomized Controlled Trial: Pilot Study. 2023.
5. Williams et al. A novel bioengineered wound product with in vitro capabilities to reduce bacteria. 2021.
6. Rodriguez et al. Microenvironment influence of a novel bioengineered wound product APIS®: An in vitro analysis of inflammatory marker and growth factor secretion. 2021.
7. Rodriguez et al. A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet. 2022.
8. Dantas et al. 2011; Li et al. 2014; Pezeshki-Modaress et al. 2014; Pezeshki-Modaress et al. 2015
9. Sell et al. 2012; Afrin et al. 2018; Johnston et al. 2018; Minden-Birkenmaier et al. 2018
10. Okabayashi et al. 2009; Majeed et al. 2012; Kawai et al. 2011; Weilin et al. 2016; Tommila et al.2008; Vilardell et al. 2016; Rodriguez et al. 2013 & 2016
* Based on clinical and in vitro data; claims have not been cleared by the FDA. Faster wound closure reported in slower healing and chronic wounds compared to standard of care.